| 引用本文: | 冯世香,王光慧,陈婷,张佳,赵娜.YTHDF1，EIF3C在上皮性卵巢癌中的表达及其临床意义[J].中国临床新医学,0,():-. |
| .YTHDF1，EIF3C在上皮性卵巢癌中的表达及其临床意义[J].中国临床新医学,0,():-. |
|
| 摘要: |
| 目的 研究YTH结构域N6-甲基腺嘌呤RNA结合蛋白1（YTHDF1），真核翻译起始因子3C（EIF3C）在上皮性卵巢癌（EOC)中的表达及临床意义。方法 回顾性分析自2016年1月至2020年1月期间我院初诊收治的130例EOC患者，以70例同期因卵巢良性囊肿行手术治疗的正常卵巢组织为对照。采用免疫组织化学检测组织YTHDF1，EIF3C表达。采用Spearman秩相关分析YTHDF1与EIF3C表达相关性。采用 Log-rank 检验和 Kaplan-Meier生存分析YTHDF1，EIF3C表达对EOC患者生存预后的影响。采用Cox 风险回归模型分析影响EOC患者预后的危险因素。结果 EOC癌组织中YTHDF1，EIF3C阳性率分别为61.54%（80/130），63.08%（82/130），高于正常卵巢组织11.43%（8/70），14.29%（10/70），差异具有统计学意义（χ2=46.368，43.606，P=0.000，0.000）。EOC癌组织中YTHDF1与EIF3C表达呈显著正相关（r=0.715，P=0.000）。肿瘤FIGO分期Ⅲ期、病理分级Ⅲ级、伴淋巴结转移EOC癌组织中YTHDF1，EIF3C阳性率高于Ⅰ～Ⅱ期，病理分级Ⅰ～Ⅱ级、无淋巴结转移癌组织，差异具有统计学意义（P均<0.05）。YTHDF1阳性和阴性组3年总生存率分别为58.75%（47/80），78.00%（39/50）。EIF3C阳性和阴性组3年总生存率分别为56.10%（46/82），83.33%（40/48）。相比于YTHDF1阴性组，EIF3C阴性组，YTHDF1阳性组，EIF3C阳性组3年累积生存率较低，差异具有统计学意义（Log-Rankχ2=6.120,10.610，P=0.013，0.001）。YTHDF1、EIF3C，FIGO分期、病理分级、淋巴结转移及CA125是影响EOC患者预后的独立因素。结论 EOC癌组织中YTHDF1，EIF3C表达升高，与不良临床病理特征有关，是潜在的EOC预后评估的肿瘤标志物。 |
| 关键词: 上皮性卵巢癌 N6-甲基腺嘌呤RNA结合蛋白1 真核翻译起始因子3C 预后 |
| DOI： |
| 分类号: |
| 基金项目:江苏省妇幼健康科研项目(F202049) |
|
| The expression and clinical significance of YTHDF1 and EIF3C in epithelial ovarian cancer |
|
|
|
Xuzhou Medical University Affiliated Hospital
|
| Abstract: |
| Objective To investigate the expression and clinical significance of the YTH domain N6-methyladenine RNA binding protein 1 (YTHDF1) and eukaryotic translation initiation factor 3C (EIF3C) in epithelial ovarian cancer (EOC). Method: A retrospective analysis was conducted on 130 EOC patients who were initially diagnosed and treated between January 2016 and January 2020, with 70 normal ovarian tissues treated with surgery for benign ovarian cysts as the control group. Immunohistochemistry was used to detect the expression of YTHDF1 and EIF3C in tissues. The correlation between YTHDF1 and EIF3C expression was analyzed using Spearman rank correlation analysis. The impact of YTHDF1 and EIF3C expression on the survival prognosis of EOC patients was analyzed using Log rank test and Kaplan Meier survival analysis. Using Cox risk regression model to analyze the risk factors affecting the prognosis of EOC patients. Results The positive rates of YTHDF1 and EIF3C in EOC cancer tissue were 61.54% (80/130) and 63.08% (82/130), respectively, which were higher than those in normal ovarian tissue by 11.43% (8/70) and 14.29% (10/70), with statistically significant differences（χ2=46.368, 43.606, P=0.000, 0.000). There was a significant positive correlation between YTHDF1 and EIF3C expression in EOC cancer tissue (r=0.715, P=0.000). The positive rates of YTHDF1 and EIF3C in EOC cancer tissues with FIGO stage III, pathological grade III, and lymph node metastasis were higher than those in stages I-II, pathological grade I-II and no lymph node metastasis in cancer tissues, and the differences were statistically significant (P<0.05). The 3-year overall survival rates of the YTHDF1 positive and negative groups were 58.75% (47/80) and 78.00% (39/50), respectively. The 3-year overall survival rates of EIF3C positive and negative groups were 56.10% (46/82) and 83.33% (40/48), respectively. The 3-year cumulative survival rate of the YTHDF1 positive group and EIF3C positive group was significantly lower than that of the YTHDF1 negative group and EIF3C negative group (Log Rank χ2=6.120,10.610, P=0.013, 0.001). YTHDF1, EIF3C, FIGO staging, pathological grading, lymph node metastasis, and CA125 were independent factors that affect the prognosis of EOC patients. Conclusion: The increased expression of YTHDF1 and EIF3C in EOC cancer tissue are associated with adverse clinical and pathological features, and are potential tumor marker for EOC prognosis evaluation. |
| Key words: Epithelial ovarian cancer N6 methyladenine RNA binding protein 1 Eukaryotic translation initiation factor 3C prognosis |
